The $400M upfront provides significant non-dilutive capital to fund Biohaven's pipeline and operations. Monitor antitrust clearance timing and milestone achievements (e.g., regulatory approvals). The royalty stream on U.S. opakalim sales could be substantial if Phase 2/3 data read out positively. SKBP's assumption of $245M in Knopp milestones removes a liability from Biohaven's balance sheet.
Price Chart
Executive Summary
Biohaven entered into a strategic global licensing agreement with SK Biopharmaceuticals for its Kv7 ion channel platform and lead candidate opakalim (BHV-7000), currently in Phase 2/3 for focal epilepsy. SKBP will pay Biohaven a $400M upfront fee ($350M at closing, $50M one year later), plus up to $150M in development/regulatory milestones and tiered royalties. Biohaven also assigned to SKBP its contingent consideration obligations under the MIPA with Knopp, which include up to $245M in milestone payments owed to Knopp. This deal provides immediate non-dilutive cash of $400M to Biohaven while transferring development and commercialization risk to SKBP.
Key Financial Metrics
Key Facts
- SKBP pays $400M total upfront to Biohaven ($350M at closing, $50M one year later)
- Biohaven eligible for up to $150M in development and regulatory milestone payments
- Tiered royalties: mid-teens to low-twenties % on U.S. net sales of opakalim; mid-single-digit % on ex-U.S. sales
- License covers Biohaven's Kv7 ion channel platform led by opakalim (BHV-7000), a selective Kv7.2/7.3 activator in Phase 2/3 for focal epilepsy
- Closing subject to antitrust clearance; Biohaven continues RISE 2/3 studies and NDA preparation post-closing
- SKBP assumes up to $245M in milestone obligations to Knopp under the MIPA assignment
- Biohaven retains no further liability for Knopp obligations post-closing
Financial Impact
$400M upfront cash (non-dilutive), up to $150M milestones, plus tiered royalties on net sales of opakalim and other Kv7 products
Risk Factors
- Closing subject to antitrust clearance; delay or failure could unwind the deal
- Opakalim Phase 2/3 data readouts remain binary; negative results would impair milestone/royalty potential
- SKBP may terminate for convenience after closing, reverting rights to Biohaven
- Competing Kv7 activators from other companies could erode market opportunity
- Biohaven still bears development costs for ongoing studies until NDA transfer
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 3 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001935979-26-000072 |
| Document: 0001935979-26-000072-index.html | 0001935979-26-000072 |
| Document: 0001935979-26-000072.txt | 0001935979-26-000072 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 22, 2026 4d ago | 8-K | $14.69 | awaiting T+5 | — | $13.88 (−5.51%) |
Oct 15, 2026 10d ago | 8-K | $10.78 $13.88 | ▲ +28.76% | ▲ +29.19% | $13.88 (+28.76%) |
Sep 9, 2026 6w ago | 8-K | $12.79 $13.89 | ▼ −8.60% | ▼ −9.10% | $13.88 (−8.52%) |
Aug 26, 2026 8w ago | 8-K | $16.95 $15.69 | ▼ −7.43% | ▼ −7.31% | $13.88 (−18.11%) |
Aug 10, 2026 10w ago | 8-K | $14.49 $13.57 | ▼ −6.35% | ▼ −5.95% | $13.88 (−4.21%) |
Jul 9, 2026 15w ago | 8-K | $15.55 $14.17 | ▼ −8.87% | ▼ −8.31% | $13.88 (−10.74%) |
May 27, 2026 21w ago | 8-K | $10.24 $11.40 | ▲ +11.33% | ▲ +11.01% | $13.88 (+35.55%) |
May 4, 2026 24w ago | 424B5 | $9.71 $9.20 | ▲ +5.25% | ▲ +7.24% | $13.88 (−42.95%) |
May 4, 2026 24w ago | S-3ASR | $9.71 $9.20 | ▼ −5.25% | ▼ −7.24% | $13.88 (+42.95%) |
May 4, 2026 24w ago | 8-K | $9.71 $9.20 | ▼ −5.25% | ▼ −7.24% | $13.88 (+42.95%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers